Avant Immunotherapeutics 1Q loss widens on charge (AP via Yahoo! Finance)

Biotechnology company Avant Immunotherapeutics Inc. said Monday its first-quarter loss widened on buyout charges. The company recorded a loss of $22.1 million, or $2.19 per share, compared with a loss of $4 million, or 49 cents per share, during the same period a year prior.

Leave a Reply

You must be logged in to post a comment.